Shares of PAVmed Inc. (NASDAQ:PAVM – Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.19 and traded as low as $1.05. PAVmed shares last traded at $1.05, with a volume of 17,961 shares traded.
Analyst Upgrades and Downgrades
Separately, Ascendiant Capital Markets decreased their target price on PAVmed from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, September 10th.
Read Our Latest Stock Analysis on PAVmed
PAVmed Price Performance
PAVmed (NASDAQ:PAVM – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.84) earnings per share for the quarter. The company had revenue of $0.98 million during the quarter. Equities research analysts forecast that PAVmed Inc. will post -5.17 earnings per share for the current year.
About PAVmed
PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.
Read More
- Five stocks we like better than PAVmed
- What is the S&P/TSX Index?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Investing in Construction Stocks
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.